VIDEO: Durability of response to bispecific antibodies 'encouraging' for lymphoma
Click Here to Manage Email Alerts
In this video, Brian T. Hill, MD, PhD, discusses important research on bispecific antibodies for the treatment of lymphoma presented at ASH Annual Meeting and Exhibition.
Long-term follow-up data on the durability of response to bispecific agents for various types of lymphoma, including diffuse large B-cell lymphoma, was highlighted at the meeting, Hill, director of the lymphoid malignancies program at Cleveland Clinic, said.
"Specifically in the case of large B-cell lymphoma, it does seem as if for those proportion of patients who achieve a complete remission, there does seem to be durability [of bispecific agents],” Hill said. "I think that is encouraging as these agents start to disseminate across oncology practices.”.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts